ANTIBIOTIC RESISTANCE OF ESBL - PRODUCING ENTEROBACTERIACEAE AT AN GIANG CENTRAL GENERAL HOSPITAL IN 2020-2021
Main Article Content
Abstract
Background: The antibiotic resistance of Extended Spectrum β-Lactamase (ESBL) Producing Enterobacteriaceae is increasing. Accurate assessment of antibiotic resistance rates in these groups of bacteria can helps medical doctors to recommend appropriate indications to their medical conditions, improve the efficiency of treatment, and minimize risks for patients. Objectives: Determination of the prevalence of ESBL-Producing Enterobacteriaceae; 2. Determination of the antibiotic resistance rate of ESBL- Producing Enterobacteriaceae. Materials and methods: A crosssectional study was conducted among 2189 ESBL infected patients treated at An Giang Central General Hospital. Results: Escherichia coli accounted for the highest rate with 64.8%, followed by Klebsiella pneumoniae with 30.2%. Proteus mirabilis and Klebsiella oxytoca accounted for 4.5% and 0.6%, respectively. Escherichia coli had the highest rate of resistance to Ampicillin, accounting for 96.5%, followed by Cefazolin, Ceftriaxone and Ciprofloxacin at 85.3%, 78.3% and 75.2%, respectively. Klebsiella pneumoniae was resistant to Ampicillin the highest rate was 92.4%, followed by Cefazolin, Ciprofloxacin and Ampicillim-Sulbactam which accounted for 60.2%, 57.1% and 56.3%, respectively. Klebsiella oxytoca was resistant to Ampicillin the highest rate was 83.3%, followed by Cefazolin, Trimethoprim-Sulfamethoxazole and Ceftriaxone with 72.7%, 66.7% and 58.3%, respectively. Proteus mirabilis resistance to Trimethoprim-Sulfamethoxazole was highest at 92.0%, followed by Ampicillin, Ciprofloxacin and Tobramycin at 90.8%, 84.0% and 72.9%, respectively. Conclusion: Escherichia coli was the most common pathogenic bacteria. Most of the species of bacteria resisted Ampicillin.
Article Details
Keywords
Antibiotic resistance, Enterobacteriaceae, ESBL
References
2. Bộ Y tế (2013), Quyết Định số 2174/QĐ-BYT (2013), Phê duyệt kế hoạch hành động quốc gia về chống kháng thuốc giai đoạn từ năm 2013 đến năm 2020.
3. Nguyễn Thị Yến Chi (2011), Khảo sát sự kháng kháng sinh của các vi khuẩn Gram âm đường ruột thường gặp trong bệnh viện sinh ESBL, Luận văn thạc sĩ Sinh học, ĐH Sư phạm Tp. Hồ Chí Minh. 4. Trần Nhật Minh (2019), Phân tích đặc điểm lâm sàng, vi sinh và phác đồ điều trị nhiễm khuẩn do Klebsiella pneumoniae tại khoa Hồi sức tích cực, Khóa luận tốt nghiệp Dược sĩ, Trường Đại học Dược Hà Nội.
5. Phạm Hồng Nhung (2018), Tình hình đề kháng kháng sinh tại khoa ICU năm 2017, Hà Nội.
6. Nguyễn Ngọc Triển (2020), Phân tích đặc điểm lâm sàng, vi sinh và sử dụng kháng sinh điều trị nhiễm khuẩn huyết do Klebsiella pneumoniae và Escherichia coli tại Viện Huyết học – Truyền máu Trung ương, Khóa luận tốt nghiệp Dược sĩ, Trường Đại học Dược Hà Nội.
7. Agency European Medicines (2017). Antimicrobial resistance, accessed 19-06-2020, from https://www.ema.europa.eu/en/human-regulatory/overview/public-healththreats/antimicrobial-resistance.
8. Chang Y. T., Coombs G., Ling T., et al. (2017), Epidemiology and trends in the antibiotic susceptibilities of Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region, 2010-2013, Int J Antimicrob Agents, 49 (6), pp.734-739.
9. Dat Vu Quoc, Vu Hieu Ngoc & et al. (2017), Bacterial bloodstream infections in a tertiary infectious diseases hospital in Northern Vietnam: aetiology, drug resistance, and treatment outcome, BMC Infectious Diseases, 17 (1), pp.493.
10. Tacconelli E, Magrini N & et al. (2017), Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics, World Health Organization, 27, pp.318-327.
11. Vardakas K. Z., Matthaiou D. K. & et al. (2015), Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit, J Infect, 70 (6), pp.592-599.